Narration
Description
Vocal Characteristics
Language
EnglishVoice Age
Young Adult (18-35)Accents
North American (General)Transcript
Note: Transcripts are generated using speech recognition software and may contain errors.
biotechnology is transforming the theory and practice of medicine, and Baxter has a clear objective in this field. The company intends to be the leading world provider of selected products and services dedicated to curing disease through biotechnology. The strategy is to build on strong existing positions in blood therapy and related areas while investing heavily in emerging gene therapies and immuno therapies. The strategy is to build on strong existing positions in blood therapy and related areas, while investing heavily in emerging gene therapies and immuno therapies. Baxter Industries has made significant progress since it announced last November a series of strategic actions to reduce costs, improve shareholder value and extend its leadership position worldwide. The actions addressed the dramatic changes underway in the U. S. Health care system and accelerate growth of the company's medical technology businesses worldwide. Baxter has reorganized its U. S sales force into cross divisional regional teams. This customer driven initiative establishes a sale structure that mirrors the emerging health care networks and a team selling approach that provides customers with one primary point of contact. The cost pressures on Baxter's US hospital customers translate directly to the company. As the country's largest distributor, of medical products. Baxter's US medical products sales team make up about half of the company's total sales volume. But the changing environment also offers opportunities, in part because Baxter has invested heavily in the last three years in programs to help hospitals reduce their costs. Cumulatively, these programs saved US hospitals more than $200 million last year. Baxter has more products than any other supplier. The strategy is to build on strong existing positions in blood therapy and related areas while investing heavily in emerging gene therapies and immuno therapies.